Current Clinical Trials

 

  • An Efficacy and Safety Trial of MK-8931 in Mild to Moderate AD A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer’s Disease.
    Sponsor Merck Sharp & Dohme Corp.
  • This study consists of two parts, Part I and Part II. The purpose of Part I of the study is to assess the efficacy and safety of MK-8931 compared with placebo administered for 78 weeks in the treatment of Alzheimer's Disease (AD). The primary study hypotheses for Part I are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score.
  • Alzheimer's Disease Prevention Trial - in patients with Mild Cognitive Impairment (MCI) Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease. Sponsor Roche Pharmaceuticals, Genetech.

  • Alzheimer's Disease Treatment Trial - in patients with Mild Alzheimer's Disease
    A Phase Iii, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy And Safety Study Of Gantenerumab In Subjects With Mild Alzheimer’s Disease

  • An Efficacy and Safety Trial of MK-8931 in Prodromal Alzheimer's Disease (MCI)
    The purpose of this trial is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer's Disease (AD), also known as prodromal AD. Participants will be randomized to receive placebo, or 12 mg or 40 mg MK-8931, once daily.
  • Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease.The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.